Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6960762 | 0.84 | SOS1 (0.54) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL22084809 | 0.82 | KDM4E (0.37) | SOS1RAD52MEN1MITFKMT2A | |
| SCHEMBL27909545 | 0.81 | SOS1 (0.51) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL21218127 | 0.79 | GNAI3 (0.51) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| Butane SCHEMBL27323486 | 0.78 | GNAI3 (0.59) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL20648825 | 0.77 | GNAI3 (0.58) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL22415116 | 0.76 | GNAI3 (0.56) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL19560897 | 0.76 | GNAI3 (0.61) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL8851791 | 0.74 | GNAI3 (0.50) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL19604920 | 0.74 | GNAI3 (0.64) | SOS1GNAI3GNAO1GNAI1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | CDC25C, CCNC, CDC25B | SOS1 1463/4885GNAI3 3349/4885GNAO1 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.